Regression of left ventricular hypertrophy following stenting of renal artery stenosis

Journal of Endovascular Therapy

Volumn 14, Issue 2, 2007, Pages 189-197

  Zeller, Thomas ^a   Rastan, Aljoscha ^a   Schwarzwälder, Uwe ^a   Müller, Christian ^b   Frank, Ulrich ^a   Bürgelin, Karlheinz ^a   Sixt, Sebastian ^a   Schwarz, Thomas ^a   Noory, Elias ^a   Neumann, Franz Josef ^a  

^a UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Atherosclerosis; Hypertension; Left ventricular hypertrophy; Renal artery stenosis; Renal artery stent; Renal ischemia; Renin angiotensin system

Indexed keywords

AGED; ANGIOPLASTY; ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; KIDNEY ARTERY STENOSIS; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STATISTICAL SIGNIFICANCE; STENT;

AGED; ANGIOPLASTY, BALLOON; ATHEROSCLEROSIS; BLOOD PRESSURE; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; PROGNOSIS; RENAL ARTERY OBSTRUCTION; RENIN-ANGIOTENSIN SYSTEM; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 34248652136     PISSN: 15266028     EISSN: None     Source Type: Journal    
DOI: 10.1583/1545-1550(2007)14[189:ROLVHF]2.0.CO;2     Document Type: Article

References (33)

1. Levy D, Garrison RJ, Savage D, et al. Left ventricular mass and incidence of coronary heart disease in an elderly cohort: the Framingham Heart Study. Ann Intern Med. 1989;110: 101-107.
2. Levy D, Garrison RJ, Savage D, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322: 1561-1566.
3. Casale PN, Devereux RB, Milner M, et al. Value of echocardiographic left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med. 1986;105: 173-178.
4. Vasan RS, Levy D. The role of hypertension in the pathogenesis of heart failure: a clinical mechanistic overview. Arch Intern Med. 1996; 156:1789-1796.
5. Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA. 1996;275:1557-1562.
6. Missouris CG, Buckenham T, Cappuccio FP, et al. Renal artery stenosis: a common and important problem in patients with peripheral vascular disease. Am J Med. 1994;96:10-14.
7. Gross CM, Krämer J, Waigand J, et al. Ostial renal artery stent placement for atherosclerotic renal artery stenosis in patients with coronary artery disease. Cath Cardiovasc Diagn. 1998; 45:1-8.
8. Jean WJ, al-Bitar I, Zwicke DL, et al. High incidence of renal artery stenosis in patients with coronary artery disease. Cath Cardiovasc Diagn. 1994;32:8-10.
9. Rimmer JM, Gennari FJ. Atherosclerotic renovascular disease and progressive renal failure. Ann Intern Med. 1993;118:712-719.
10. Caps MT, Zierler RE, Polissar NL, et al. Risk of atrophy in kidneys with atherosclerotic renal artery stenosis. Kidney Int. 1998;53:735-742.
11. Mailloux LU, Napolitano B, Bellucci AG, et al. Renal vascular disease causing end-stage renal disease, incidence, clinical correlates, and outcomes: a 20-year clinical experience. Am J Kidney Dis. 1994;4:622-629.
12. Klag N, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal artery disease in men. N Engl J Med. 1996;334:13-18.
13. Border WA, Noble NA. Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension. 1998;31:161-188.
14. Safian RD, Textor SC. Renal-artery stenosis. N Engl J Med. 2001;344:431-442.
15. Bloch MJ, Trost DW, Pickering TG, et al. Prevention of recurrent pulmonary edema in patients with bilateral renovascular disease through renal artery stent placement. Am J Hypertens. 1999;12:1-7.
16. Symonides B, Chodakowska J, Januszewicz A, et al. Effects of the correction of renal artery stenosis on blood pressure, renal function and left ventricular morphology. Blood Pressure. 1999;8:141-150.
17. Yoshitomi Y, Nishikimi T, Abe H, et al. Comparison of changes in cardiac structure after treatment in secondary hypertension. Hypertension. 1996;27:319-323.
18. Zeller T, Frank U, Späth M. Color duplex ultrasound imaging of renal arteries and detection of hemodynamically relevant renal artery stenoses [in German]. Zeitschr Ultraschall Med. 2001;22:116-121.
19. Zeller T, Müller C, Frank U, et al. Goldcoating and restenosis after primary stenting of ostial renal artery stenosis. Cath Cardiovasc Interv. 2003;60:1-6.
20. Devereux RB, Lutas EM, Casale PN, et al. Echocardiograpic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450-458.
21. de Simone D, Devereux RB, Daniels SR, et al. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol. 1995;25:1056-1062.
22. Wright JR, Shurrab AE, Cooper A, et al. Left ventricular morphology and function in patients with atherosclerotic renovascular disease. J Am Soc Nephrol. 2005;16:2746-2753.
23. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45:720-721.
24. Devereux RB, Dahlof B, Gerdts E, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation. 2004; 110:1456-1462.
25. Ehmke H, Faulhaber J, Munter K, et al. Chronic ETA receptor blockade attenuates cardiac hypertrophy independently of blood pressure effects in renovascular hypertensive rats. Hypertension. 1999;33:954-960.
26. Duprez DA, Bauwens FR, De Buyzere ML, et al. Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol. 1986;58: 575-582.
27. Vasan RS, Evans JC, Larson MG, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004;351:8-10.
28. Vasan RS, Evans JC, Benjamin EJ, et al. Relations of serum aldosterone to cardiac structure: gender-related differences in the Framingham Heart Study. Hypertension. 2004; 43:957-962.
29. Devereux RB, Wachtell K, Gerdts E, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA. 2004;292:2396-2398.
30. Greenberg B, Quinones MA, Koilpillai C, et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation. 1995;91:2573-2581.
31. Cohn JN, Tognoni G. for the Valsartan Heart Failure Trial investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675.
32. Pitt B. Aldosterone blockade in patients with systolic left ventricular dysfunction. Circulation. 2003;108:1790-1794.
33. Zeller T, Frank U, Müller C, et al. Predictors of improved renal function after primary stenting of severe atherosclerotic ostial renal artery stenosis. Circulation. 2003;108:2244-2249.